Sustained reduction in disability with alemtuzumab is associated with durable quality-of-life improvement on SF-36 over 4 years in CARE-MS II patients with RRMS though most were treatment-free after year 1
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Sustained reduction in disability with alemtuzumab is associated with durable quality-of-life improvement on SF-36 over 4 years in CARE-MS II patients with RRMS though most were treatment-free after year 1 |
| Type de publication | Journal Article |
| Year of Publication | 2015 |
| Auteurs | R. Gonzalez A, Moreau T., Hartung H.-P, Hupperts R.M, Kita M., Margolin D.H, Kasten L., Giovannoni G., Investigators CARE-MSII |
| Journal | MULTIPLE SCLEROSIS JOURNAL |
| Volume | 21 |
| Pagination | 600-601 |
| Date Published | SEP |
| Type of Article | Meeting Abstract |
| ISSN | 1352-4585 |